【摘要】 目的观察来氟米特治疗免疫介导性肾脏病的疗效与安全性。方法免疫介导性肾脏病患者40例随机分为2组,每组20例,治疗组予激素联合来氟米特,对照组予激素联合环磷酰胺治疗,治疗0.5~1年后比较2组临床缓解率和不良反应发生率。结果治疗组总有效率高于对照组(90.0%vs 40.0%,P<0.01);治疗后2组患者血清白蛋白水平均不同程度上升(P<0.05,P<0.01),除对照组三酰甘油外,2组24 h尿蛋白定量、血肌酐等指标水平均不同程度下降(P<0.01),而治疗组较对照组改善更明显(P<0.01);不良反应发生率及严重程度均低于对照组(25.0%vs 70.0%,P<0.01)。结论来氟米特治疗免疫介导性肾脏病效果优于环磷酰胺,且安全性高。更多还原

【Abstract】 Objective To observe the efficacy and safety of lefluiiomide in the treatment of immune mediated nephropathy,explore its application prospects.Methods 40 cases of immune mediated nephropathy were randomly divided into 2 groups,20 cases received hormones combined with lefluiiomide treatment(treatment group),20 cases received hormone in combination with cyclophosphamide therapy as control group.After a course of treatment(about six months to 1 year),the clinical remission rate differences in the incidence and adverse reactions were compared between the two groups.Results After treatment,efficacy in the treatment group compared with the control group was significantly(90.0%vs.40.0%,P < 0.01);the patients serum albumin levels were increased with varying degrees(P <0.05,P <0.01),24 hour urinary protein,serum creatinine,blood triglycerides(except control group) and other indicators were decreased of varying degrees(P < 0.01),treatment group incidence of adverse reactions and severity were lower than the control group(25.0%vs.70.0%,P < 0.01).Conclusion Lefluiiomide in the treatment of immune mediated nephropathy is more efficient than cyclophosphamide,and adverse reactions lower than cyclophosphamide.更多还原